After a year of gathering feedback from regulators following completion of its phase II study, Soligenix Inc. said it reached accord with the FDA to advance SGX-942 (dusquetide) into a pivotal phase III study to treat oral mucositis in head and neck cancer (HNC) patients treated with chemoradiation (CRT).